- \n
- Vyome has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1<\/sup><\/i><\/li>\n
- VT-1953 regulatory submissions to the FDA for Orphan Drug Designation status and proposals for constructive FDA guidance on the next steps of development<\/i><\/li>\n
- Company ends Q1 2026 with approximately $8.8 million in cash and cash equivalents while maintaining a clean capital structure with no debt, no preferred stock, and no toxic financing instruments<\/i><\/li>\n<\/ul>\n
CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nVyome Holdings, Inc. (Nasdaq: HIND)(\u201cVyome\u201d), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update.<\/p>\n\nKrishna Gupta, Chairman of Vyome, said, \u201cOver the last several quarters, Vyome has executed with focus and discipline, advancing differentiated programs in areas of significant unmet medical need focused on inflammatory disorders. Inflammation remains one of the world\u2019s largest problems, and we believe Vyome is well positioned for long-term value creation. We continue to strengthen our scientific, operational, and governance foundation while remaining highly disciplined on capital structure and shareholder alignment.\u201d<\/p>\n
\nVenkat Nelabhotla, CEO of Vyome, stated, \u201cWe continue to advance VT-1953 toward pivotal-stage readiness while maintaining a strong focus on disciplined execution, regulatory engagement, manufacturing preparedness, and financial stewardship. We submitted to the FDA an application for the approval of orphan drug designation status and proposals across several areas of the next stages of development readiness, and continue to believe VT-1953 addresses a major unmet need in malignant fungating wounds, where there are currently no FDA-approved therapies specifically addressing the condition.\u201d<\/p>\n
\n\u201cImportantly, we have continued to preserve what we believe is one of the Company\u2019s key differentiators: a clean and disciplined capital structure with no debt, no preferred stock, and no toxic financing instruments. We remain focused on creating long-term shareholder value while advancing our immuno-inflammatory and rare disease strategy,\u201d concluded Mr. Nelabhotla.<\/p>\n
First Quarter 2026 and Recent Corporate Highlights<\/i><\/b><\/p>\n
- \n
- \nRegulatory submissions with the FDA related to VT-1953 pivotal development readiness, including discussions involving manufacturing, toxicology, pharmacokinetic requirements, and clinical development considerations. Filed an Orphan Drug Designation application with the FDA<\/p>\n<\/li>\n
- \nContinued advancement of VT-1953 for malignant fungating wounds, a condition associated with significant unmet medical need and no FDA-approved therapies specifically addressing the condition<\/p>\n<\/li>\n
- \nRaised approximately $5.29 million in gross proceeds through the sale of 1,089,545 common shares on January 27, 2026, at an average price of $5.00 per share, representing a 59.2% premium to the prior day\u2019s closing price, with total dilution to existing shareholders of approximately 15%<\/p>\n<\/li>\n
- \nContinued scientific and translational activities supporting VT-1908 and broader immuno-inflammatory initiatives<\/p>\n<\/li>\n
- \nPresented positive VT-1953 Phase 2 clinical study data at the prestigious American Association for Cancer Research (AACR) 2026<\/p>\n<\/li>\n
- \nEntered into a strategic in-licensing agreement with Impetis Biosciences Limited, a TATA Enterprise, for selective JAK inhibitor assets under a capital-light structure with payments at commercialization, and development using non-dilutive pathways<\/p>\n<\/li>\n<\/ul>\n
Financial Results for the Quarter Ended March 31, 2026<\/b><\/p>\n
- \n
- \nCash and cash equivalents were approximately $8.8 million as of March 31, 2026, compared with approximately $5.0 million as of December 31, 2025<\/p>\n<\/li>\n
- \nTotal assets were approximately $10.2 million as of March 31, 2026<\/p>\n<\/li>\n
- \nTotal stockholders\u2019 equity was approximately $8.0 million as of March 31, 2026<\/p>\n<\/li>\n
- \nTotal operating expenses for the quarter ended March 31, 2026, were approximately $1.1 million, including approximately $666,000 in research and development expenses and approximately $478,000 in selling, general, and administrative expenses<\/p>\n<\/li>\n
- \nNet loss attributable to common shareholders for the quarter ended March 31, 2026, was approximately $963,000, or approximately $0.15 per basic and diluted share<\/p>\n<\/li>\n<\/ul>\n
The Company will also host a conference call and webcast on Wednesday, June 3, 2026, at 11:00 a.m. ET to discuss the results. To access the webcast, please use the following link: https:\/\/event.choruscall.com\/mediaframe\/webcast.html?webcastid=531gpp9T<\/a> or dial in at 1-877-317-6789 (U.S.\/Canada toll-free) or +1-412-317-6789 (international).<\/i><\/b><\/p>\n
A replay will be available on the Company Website.<\/i><\/b><\/p>\n
About Vyome Holdings, Inc.:<\/b><\/p>\n
\nVyome is building the world\u2019s premier platform spanning the US-India innovation corridor. Vyome\u2019s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety.<\/p>\n
\n
\n \n SUMMARY FINANCIAL STATEMENTS<\/b><\/p>\n
SUMMARY OF CONDENSED CONSOLIDATED BALANCE SHEETS AS OF<\/i><\/p>\n<\/td>\n<\/tr>\n
\n <\/tr>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n March 31, 2026<\/b><\/p>\n<\/td>\n
\n \n December 31, 2025<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nCash and cash equivalents<\/p>\n<\/td>\n
\n \n$<\/p>\n<\/td>\n
\n \n8,795,783<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n4,982,333<\/p>\n<\/td>\n<\/tr>\n
\n \n \nOther current assets<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n366,799<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n455,988<\/p>\n<\/td>\n<\/tr>\n
\n \n \nLong term assets<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n 1,022,864<\/span><\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n 1,058,856<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n \nTotal assets<\/p>\n<\/td>\n
\n $<\/span><\/p>\n<\/td>\n
\n \n10,185,446<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n6,497,177<\/p>\n<\/td>\n<\/tr>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \nLiabilities<\/p>\n<\/td>\n
\n \n$<\/p>\n<\/td>\n
\n \n2,144,125<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n2,735,160<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTotal Stockholders\u2019 equity (deficit)<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n8,041,321<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,762,017<\/p>\n<\/td>\n<\/tr>\n
\n \n \nTotal liabilities and stockholders\u2019 equity<\/p>\n<\/td>\n
\n \n$<\/p>\n<\/td>\n
\n \n10,185,446<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n6,497,177<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
- VT-1953 regulatory submissions to the FDA for Orphan Drug Designation status and proposals for constructive FDA guidance on the next steps of development<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260528750612\/en\/2817332\/3\/Vyome_New_Logo_2025.jpg\"){kind=logo}
<\/td>\n<\/tr>\n